Acurx Pharmaceuticals Business Summary

Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company that operates through a development-focused business model, currently generating value through the advancement of its proprietary pipeline with a long-term revenue strategy centered on product commercialization and strategic licensing. The company specializes in a novel class of small-molecule antibiotics with a Gram-positive selective spectrum (GPSS) that inhibit the DNA polymerase IIIC (pol IIIC) enzyme, a mechanism designed to eradicate priority pathogens while preserving the healthy gut microbiome. Its primary business segment is the clinical development of its lead candidate, ibezapolstat, which is transitioning into international Phase 3 trials for Clostridioides difficile infection (CDI), alongside preclinical assets like ACX-375C targeting MRSA and VRE. Acurx competes with established antibiotic developers such as Spero Therapeutics, Melinta Therapeutics, and Paratek Pharmaceuticals, positioning itself as a specialized innovator in microbiome-sparing infectious disease treatments with a lean, high-efficiency operational structure. The company was co-founded by Robert J. DeLuccia and David P. Luci, a leadership duo with a track record of leading antibiotic-focused biotechs, including their previous venture, Dipexium Pharmaceuticals. David P. Luci serves as President and CEO, leveraging his background as a CPA and corporate attorney with expertise in healthcare finance and M&A from his tenure at Paul Hastings LLP and Bioenvision. Executive Chairman Robert J. DeLuccia brings extensive commercial pedigree from Pfizer, where he served as Vice President of Marketing and Sales Operations. The executive team is supported by co-founder and CFO Robert G. Shawah, formerly of Dipexium, and a board of directors that includes industry veterans like Joseph Scodari and Dr. Jack Dean. Notable institutional backing is provided by Armistice Capital, Vanguard, and BlackRock, alongside a strategic financing agreement with Lincoln Park Capital Fund.